Healthcare
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiativesWATERTOWN, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Tarek S. Hassan, M.D., as Senior Vice President, Chief Strategic Science Office
About this update from Eyepoint, Inc.
Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiatives WATERTOWN, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Tarek S. Hassan, M.D., as Senior Vice President, Chief Strategic Science Officer. Dr. Hassan will report directly to Jay S. Duker, M.D., President and CEO of EyePoint, and will serve as a member of the executive leadership team. A globally recognized retina specialist and key opinion leader with more than 35 years of experience, Dr. Hassan will provide strategic guidance across the Company's portfolio to optimize development, potential commercialization, and growth opportunities for EyePoint's pipeline, including its lead program, DURAVYU™ (vorolanib intravitreal insert). "We are pleased to welcome Dr. Hassan to the EyePoint leadership team at an important time for the Company, as topline data for our Phase 3 wet age-related macular degeneration trials for DURAVYU are expected in the near future," said Dr. Duker. "Dr. Hassan's extensive clinical development expertise, proven track record in ophthalmology, and deep understanding of the therapeutic innovation required to meaningfully improve the treatment paradigm for serious retinal diseases will strengthen our strategic decision-making as we advance DURAVYU, evaluate future growth opportunities, and build long-term value for patients and shareholders." Dr. Hassan is currently Professor of Ophthalmology at Oakland University William Beaumont School of Medicine and a Senior Partner at Associated Retinal Consultants in Royal Oak, Michigan. He has held leadership roles across several major global retinal organizations, including serving as Past President of the American Society of Retina Specialists (ASRS), the Foundation of the ASRS, the Retina World Congress (RWC), which he co-founded, and the Retina Hall of Fame. Throughout his career, Dr. Hassan has participated in more than 180 multicenter clinical trials, authored more than 250 peer-reviewed publications, and delivered more than 860 scientific presentations nationally and internationally. He has been named to Best Doctors in America every year since 2000 and was an inaugural inductee of the Retina Hall of Fame. Dr. Hassan earned his B.S. with Highest Distinction in Biology, his B.S. in Psychology, and his M.D. from the University of Michigan before completing his ophthalmology residency at the University of Michigan's W.K. Kellogg Eye Center. He completed his fellowship in vitreoretinal disease and surgery at Associated Retinal Consultants within William Beaumont Hospital in Royal Oak, Michigan.